ArticleJACC. Case reports2026
Reverse Takotsubo Cardiomyopathy Caused by Repeated Guanfacine Overdose.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuanfacine, an α2A receptor agonist, is prescribed to reduce cerebral neural activity in patients with attention-deficit hyperactivity disorder. CASE SUMMARY: We present the case of a 15-year-old girl who overdosed on extended-release guanfacine 3 times. This resulted in 2 episodes of reverse takotsubo cardiomyopathy with respiratory failure requiring mechanical ventilation, followed by late QT prolongation and spontaneous recovery. DISCUSSION: The prominent characteristic of this case was the blood guanfacine concentration-dependent development of reverse takotsubo cardiomyopathy, providing insights into the underlying mechanisms. TAKE-HOME MESSAGES: An overdose of guanfacine, a medication used for treating attention-deficit hyperactivity disorder, can result in reverse takotsubo cardiomyopathy in a blood concentration-dependent manner. The cardiopulmonary time course of an extended-release guanfacine overdose spans approximately 2 weeks, with early critical respiratory failure, reverse takotsubo cardiomyopathy, and late QT prolongation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.